Nasopharyngeal Carcinoma
Conditions
Brief summary
The investigators aim to evaluate the survival benefit from triple combination of induction, concurrent and aduvant chemotherapy versus concurrent chemotherapy alone for high risk locoregionally advanced nasopharyngeal carcinoma treated with intensity-modulated radiotherapy.
Detailed description
All eligible patients receive intensity-modulated radiotherapy (IMRT) with a total dose of 68 to 70 Gy in 33 fractions to the primary tumor. Patients in the experimental arm receive triple therapy of induction, concurrent and adjuvant chemotherapy. Induction chemotherapy consists of docetaxel 75 mg/m², D1 and cisplatin 25 mg/m², D1-3 every 3 weeks for 2 cycles. Concurrent chemotherapy in the experimental arm consists of cisplatin 25 mg/m², D1-3 every 3 weeks and Xeloda 2000mg/m², D1-14 for 3 cycles. Adjuvant chemotherapy consists of Xeloda 2500mg/m², D1-14 for 2 cycles. Concurrent chemotherapy in the control arm consists of cisplatin 100 mg/m², D1 every 3 weeks for 3 cycles.The primary endpoint is failure-free survival (FFS). Secondary end points include overall survival (OS), locoregional relapse-free survival (LRFS), distant metastasis-free survival (DMFS) and the incidence of grade 3 or higher acute toxicities. All efficacy analyses are conducted in the intention-to-treat population, and the safety population include only patients who receive their randomly assigned treatment.
Interventions
DRUGCisplatin 2
Cisplatin 100 mg/m2, D1
DRUGDocetaxel
Docetaxel 60mg/m2, D1
DRUGXeloda
Xeloda 2000mg/m2, D1-14 in concurrent chemotherapy and Xeloda 2500mg/m2, D1-14 in adjuvant chemotherapy
RADIATIONIntensity-modulated radiotherapy
Intensity-modulated radiotherapy
DRUGCisplatin 1
Cisplatin 25 mg/m2, D1-3
Sponsors
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
The First Affiliated Hospital of Guangzhou Medical University
The First Affiliated Hospital of Guangdong Pharmaceutical University
Sun Yat-sen University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Newly histologically confirmed non-keratinizing (WHO 1991) nasopharyngeal carcinoma. * Tumor staged as T4N0-3M0 or T1-3N3M0 (the 2010 UICC/AJCC staging system). * Pretreatment EBV DNA ≥ 4000 copies/mL. * Karnofsky scale (KPS) ≥ 70. * Adequate marrow: leucocyte count ≥ 4×10E9/L, hemoglobin ≥ 110g/L and platelet count ≥ 100×10E9/L. * Normal liver function test: Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and bilirubin ≤ 1.5×upper limit of normal (ULN) concomitant with alkaline phosphatase (ALP) ≤ 2.5×ULN. * Adequate renal function: creatinine clearance ≥ 60 ml/min or creatinine ≤ 1.5×ULN. * Patients must give written informed consent.
Exclusion criteria
* Prior malignancy, except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer. * Pregnancy or lactation (consider pregnancy test in women of child-bearing age and emphasize effective contraception during the treatment period). * History of previous radiotherapy (except for non-melanomatous skin cancers outside intended radiotherapy volume). * Prior radiotherapy, chemotherapy or surgery (except diagnostic) to primary tumor or nodes. * Any severe intercurrent disease, which may bring unacceptable risk or affect the compliance of the trial, for example, unstable cardiac disease requiring treatment, renal disease, chronic hepatitis, diabetes with poor control (fasting plasma glucose \> 1.5×ULN), and emotional disturbance. * Dihydropyrimidine dehydrogenase deficiency.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| failure-free survival | Two year |
Secondary
| Measure | Time frame |
|---|---|
| overall survival | two year |
| distant metastasis-free survival | two year |
| locoregional relapse-free survival | two year |
| Number of participants with treatment-related acute adverse events as assessed by CTCAE v4.0 | two months |
Countries
China
Contacts
Primary ContactFang-Yun Xie, M.D.
Backup ContactPu-Yun OuYang, M.D.
Outcome results
None listed